4 results about "Mycobacterium" patented technology

The invention provides a reinforced mosaic gene recombinant bacillus calmette-guerin, which comprises a recombinant shuttle expression vector guided into bacillus calmette-guerin (BCG) by an electro-transformation method and cloned with a bacillus tubercle mosaic gene Ag85A-ESAT6. The invention also provides a preparation method for the reinforced mosaic gene recombinant bacillus calmette-guerin and application thereof to preparation of recombinant vaccines for preventing tuberculosis. A mycobacterium differential expression system or other shuttle expression plasmid is used as the vector so as to realize high-level expression of the bacillus tubercle mosaic gene in the bacillus calmette-guerin. The reinforced mosaic gene recombinant bacillus calmette-guerin can produce reinforced TH1-type immune response aiming at Ag85A and ESAT-6 antigenic specificities respectively, and is expected to become a novel tuberculosis vaccine for replacing the bacillus calmette-guerin.

The invention discloses one group of nucleic acid aptamers capable of specifically bonding with tuberculosis mycobacterium Beijing genotype strain surface lipolysaccharide namely mannose modified mannosylated lipoarabinomannan (ManLAM) and application of the nucleic acid aptamers. The aptamers are specific to small-molecular single-chain DNA (ssDNA) of the ManLAM, and have a nucleotide sequence as shown in the SEQ ID No.1-5. The ssDNA has functions similar to those of a monoclonal antibody, and can be directly and specifically bonded with ManLAM. By adopting an enzyme-linked oligonucleotide assay (ELONA) method, the ManLAM antigen in serum of patients with pulmonary tuberculosis, extrapulmanory tuberculosis and the like can be quickly effectively detected in 2 hours, the ManLAM antigen in sputum of an active pulmonary tuberculosis patient can be directly identified, and the detection sensitivity on the Man LAM antigen can be 0.035mu g/mL. The aptamers are simple to prepare and low in cost, and can be used as an effective novel reagent for diagnosing the mycobacterium tuberculosis antigen of early and latent tuberculosis.

The present invention provides a safer way to intubate patients having communicable diseases, such as bacterial and viral infections. It protects health care professionals performing the intubation from bodily fluids of the patients that might otherwise be projected directly onto them by coughing, gagging, vomiting, or sneezing. Additionally, it traps airborne suspensions or aerosols containing pathogens, such as bacterial, myco-bacterial, viral, or fungal infections, originating from the patient and keeps them from entering into the air in close proximity to the healthcare professionals. The contaminated air can then be vented to a location which is away from personnel, such as an outdoor containment area. In one embodiment of this invention the contaminated air is passed through a disinfecting solution which destroys the pathogens before the air is recycled into the environment, such as the room where the intubation is carried out.